Channel Therapeutics Corporation (CHRO)
Jul 2, 2025 - CHRO was delisted (reason: merged into PTHS)
13.50
0.00 (0.00%)
Inactive · Last trade price
on Jul 1, 2025
Channel Therapeutics Employees
As of December 31, 2024, Channel Therapeutics had 11 total employees, including 4 full-time and 7 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$669,147
Market Cap
8.90M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11 | 3 | 37.50% |
Dec 31, 2023 | 8 | 6 | 300.00% |
Dec 31, 2022 | 2 | 0 | - |
Dec 31, 2021 | 2 | - | - |
CHRO News
- 6 days ago - Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement - GlobeNewsWire
- 2 months ago - Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - GlobeNewsWire
- 6 months ago - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - GlobeNewsWire
- 7 months ago - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - GlobeNewsWire
- 8 months ago - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - GlobeNewsWire
- 8 months ago - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - GlobeNewsWire
- 9 months ago - Chromocell Announces Amendment to Stock Repurchase Plan - GlobeNewsWire
- 10 months ago - Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewsWire